Addiction medicine

EQS-News: Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Sunday, January 22, 2023

New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Thursday, January 5, 2023

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Shatterproof Applauds the Passage of the MATE Act to Expand Addiction Education

Retrieved on: 
Friday, December 23, 2022

Shatterproof applauds the passage of the Medication Access and Training Expansion (MATE) Act (H.R.

Key Points: 
  • Shatterproof applauds the passage of the Medication Access and Training Expansion (MATE) Act (H.R.
  • Passage of the MAT Act along with the MATE Act will enable better access to life-saving treatment.
  • The MATE Act mainstreams addiction medical education on SUDs across the nation’s medical educational programs.
  • Shatterproof worked closely with the American Society of Addiction Medicine on the passing of the MATE Act.

All Points North Creates New Medical Board to Foster Early Adoption in Mental Healthcare

Retrieved on: 
Wednesday, January 4, 2023

All Points North (APN) , the only whole-person health company offering innovative treatment for the mind, body and soul across the full continuum of care, has appointed three industry experts and practicing doctors to its Medical Board .

Key Points: 
  • All Points North (APN) , the only whole-person health company offering innovative treatment for the mind, body and soul across the full continuum of care, has appointed three industry experts and practicing doctors to its Medical Board .
  • “APN is committed to providing exceptional care across an array of behavioral health and addiction service platforms,” said Founder and CEO Noah Nordheimer.
  • The Medical Board members are uniquely positioned for this role given their backgrounds:
    Dr. Daly is a board-certified psychiatrist with a masters in biological sciences from the University of Cambridge.
  • “This board allows us to implement newer modalities quickly, without sacrificing the safety and incredibly positive outcomes we’ve seen in our clients.”
    For more information on APN, please visit www.apn.com .

Discovery Behavioral Health Wraps 2022 With Acquisitions of Leading Treatment Centers and Expansion into Major Markets, Executive Appointments, and Launch of DiscoveryMD

Retrieved on: 
Wednesday, January 4, 2023

As well, the company announced several C-suite appointments and the launch of a new division, DiscoveryMD.

Key Points: 
  • As well, the company announced several C-suite appointments and the launch of a new division, DiscoveryMD.
  • In February, DBH began the year by acquiring Dan Med TMS Neuro Institute, a leading treatment center specializing in TMS therapy for depression.
  • "In 2022 we continued to build upon the foundation of our unprecedented expansion of traditional and virtual care in 2021.
  • That's why Discovery Behavioral Health has made evidence-based, outcome driven healthcare accessible and affordable since inception.

Symposium to Address Suicidality, Bridging Toxicology and Mental Health

Retrieved on: 
Friday, December 9, 2022

Phoenix, AZ, Dec. 09, 2022 (GLOBE NEWSWIRE) -- After a 2-year hiatus from in-person activities, The American College of Medical Toxicology (ACMT ) is pleased to present a full-day symposium exploring the intersection of medical toxicology and mental health.

Key Points: 
  • Phoenix, AZ, Dec. 09, 2022 (GLOBE NEWSWIRE) -- After a 2-year hiatus from in-person activities, The American College of Medical Toxicology (ACMT ) is pleased to present a full-day symposium exploring the intersection of medical toxicology and mental health.
  • The event, titled “ Self-Harm, Suicidality, and the Poisoned Patient: The Intersection of Toxicology and Mental Health ,” will take place on Thursday, March 30, 2023 at the San Diego Marriott La Jolla.
  • This program brings together distinguished experts in Medical Toxicology, Psychiatry, Emergency Medicine, Medical Ethics, Military Medicine, Addiction Medicine, Public Health and related fields.
  • The American College of Medical Toxicology (ACMT) is a professional, nonprofit association of physicians with recognized expertise and board certification in medical toxicology.

Progressive Diagnostics Opens New Shelton Patient Service Center

Retrieved on: 
Wednesday, December 14, 2022

TRUMBULL, Conn., Dec. 14, 2022 /PRNewswire/ -- Progressive Diagnostics has moved its patient lab testing center from Commerce Drive to the Shelton Pointe medical office building located at 2 Trap Falls, Suite 105 in Shelton.

Key Points: 
  • TRUMBULL, Conn., Dec. 14, 2022 /PRNewswire/ -- Progressive Diagnostics has moved its patient lab testing center from Commerce Drive to the Shelton Pointe medical office building located at 2 Trap Falls, Suite 105 in Shelton.
  • All Progressive Diagnostics' lab testing centers offer same-day results for COVID-19, flu, RSV, and antibody tests and accepts commercial, Medicare and Medicaid insurances.
  • The 5,000 square foot, first floor location gives residents of Fairfield County easy access to Progressive Diagnostics' laboratory tests.
  • Founded in 2014, Progressive Diagnostics is part of the Progressive Group of companies that also includes the Progressive Institute and Progressive Health Dynamics.

New Study Published on JAMA Network Finds Connection Between Mental Illness and Unmet Social Needs Among Seniors

Retrieved on: 
Wednesday, December 7, 2022

LOS ANGELES, Dec. 7, 2022 /PRNewswire/ -- A  new study of 56,000 senior Americans published on JAMA Network, the online publication of the Journal of the American Medical Association, has found the prevalence and risks associated with health-related social needs, including food insecurity and inadequate housing, and mental illness.

Key Points: 
  • In this large cohort study of Medicare Advantage enrollees with and without mental illness, 38.6% had at least 1 mental illness diagnosis, 54.0% had a health-related social need (HRSN), and 25.3% had both mental illness and an HRSN in the past year.
  • The association of mental illness with the presence of HRSNs was most substantial among those with both serious and persistent mental illness.
  • Compared with the general population, those with mental illness have higher morbidity and mortality, and those with serious mental illness die a decade earlier.
  • Although many individuals in the U.S. have HRSNs, those with mental illness are at particularly high risk.

Alan A. Wartenberg, MD, is recognized by Continental Who's Who

Retrieved on: 
Monday, December 5, 2022

Dr. Wartenberg received his Bachelor of Arts degree at New York University and his Medical Doctor (M.D.)

Key Points: 
  • Dr. Wartenberg received his Bachelor of Arts degree at New York University and his Medical Doctor (M.D.)
  • He completed his rotating internship at Harbor-UCLA Medical Center and his residency in internal medicine at Milwaukee County Medical Center.
  • He is an experienced addiction medicine specialist and is currently a medical director at MAP Health Management in Rhode Island.
  • In his spare time, the doctor enjoys being with his family, including two grandchildren he hopes to encourage to have a love for microbiology.

NaxSwab™ OTC novel naloxone nasal swab demonstrates faster absorption and higher early exposures against other naloxone products in clinical study

Retrieved on: 
Thursday, December 1, 2022

BETHESDA, Md., Dec. 1, 2022 /PRNewswire/ -- Pocket Naloxone Corp., a startup pharmaceutical company with the vision of enhancing naloxone delivery, today announced positive results from its human pharmacokinetic (PK) study of its novel naloxone nasal swab NaxSwab™. The study was a randomized, crossover, comparative bioavailability study that enrolled sixty healthy volunteers to evaluate naloxone absorption against the primary reference drug 0.4mg intramuscular (IM) naloxone injection and against naloxone HCI 4mg nasal spray as a secondary comparator. Results indicate more rapid absorption against these reference naloxone products and good safety and tolerability.

Key Points: 
  • The study was a randomized, crossover, comparative bioavailability study that enrolled sixty healthy volunteers to evaluate naloxone absorption againstthe primary reference drug 0.4mg intramuscular (IM) naloxone injection and against naloxone HCI 4mg nasal spray as a secondary comparator.
  • Results indicatemore rapid absorption against these reference naloxone products and good safety and tolerability.
  • Clinical practitioners believe that faster naloxone absorption into the bloodstream could provide an advantage to help revive someone in the presence of highly potent synthetic opioids like fentanyl.
  • NaxSwabwas associated with a 74% higher naloxone exposure at 2.5 minutes post-dose and 19% higher naloxone exposure at 5 minutes post-dose compared to 4 mg naloxone spray.